Skip to main content

Animations

MJFF Publications

1451 - 1460 of 8825 Results
Title
Year
  • Year
  • 2016
  • 2017
  • 2021
  • 2018
  • 2015
  • 2021
  • 2016
  • 2017
  • 2018
  • 2017
  • Summary Details
    OPEN
    Title: Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia
    Journal Name: Cortex
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.cortex.2016.07.004
    Citation Count: 20
  • Summary Details
    OPEN
    Title: GBA mutations in Parkinson disease: earlier death but similar neuropathological features
    Journal Name: European Journal of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/ene.13395
    Citation Count: 29
  • Summary Details
    OPEN
    Title: Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy
    Journal Name: ACS Pharmacology & Translational Science
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acsptsci.0c00162
    Citation Count: 24
  • Summary Details
    RESTRICTED
    Title: Molecular rotors report on changes in live cell plasma membrane microviscosity upon interaction with beta-amyloid aggregates
    Journal Name: Soft Matter
    Publisher: Royal Society of Chemistry (RSC)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1039/c8sm01633j
    Citation Count: 40
  • Summary Details
    RESTRICTED
    Title: Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents l-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice
    Journal Name: Neuroscience
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuroscience.2015.07.032
    Citation Count: 17
  • Summary Details
    OPEN
    Title: Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease models
    Journal Name: JCI Insight
    Publisher: American Society for Clinical Investigation
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1172/jci.insight.148649
    Citation Count: 7
  • Summary Details
    OPEN
    Title: The polarity protein Par3 regulates APP trafficking and processing through the endocytic adaptor protein Numb
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.nbd.2016.03.022
    Citation Count: 26
  • Summary Details
    OPEN
    Title: Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype
    Journal Name: Annals of Clinical and Translational Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/acn3.447
    Citation Count: 15
  • Summary Details
    OPEN
    Title: Understanding the role of genetic variability in LRRK2 in Indian population
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27558
    Citation Count: 14
  • Summary Details
    RESTRICTED
    Title: Chelerythrine promotes Ca2+-dependent calpain activation in neuronal cells in a PKC-independent manner
    Journal Name: Biochimica et Biophysica Acta (BBA) - General Subjects
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.bbagen.2017.01.021
    Citation Count: 18
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.